NR1H4 and metabolic dysfunction-associated steatohepatitis: Specifically, FXR activation controls lipid metabolism and bile acid synthesis [13,14], and the pharmacological exploitation of FXR has led to the discovery of FXR agonists that have proven effective in reducing steatohepatitis in NAFLD and NASH patients [5,15].